Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial

被引：262

作者：

Buttgereit, Frank ^{[1
]}

Doering, Gisela ^{[2
]}

Schaeffler, Achim ^{[3
]}

Witte, Stephan ^{[3
]}

Sierakowski, Stanislaw ^{[4
]}

Gromnica-Ihle, Erika ^{[5
]}

Jeka, Slawomir ^{[6
]}

Krueger, Klaus ^{[7
]}

Szechinski, Jacek ^{[8
]}

Alten, Rieke ^{[9
]}

机构：

[1] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany

[2] Merck KGaA, Darmstadt, Germany

[3] Nitec Pharma GmbH, Mannheim, Germany

[4] Ctr Miriada, Prywatny Gabinet Specialistyc, Bialystok, Poland

[5] Immanuel Krankenhaus, Berlin, Germany

[6] Clin Trials Off, Torun, Poland

[7] Praxiszentrum St Bonifatius, Munich, Germany

[8] Katedra & Klin Reumatol & Chorob Wewnetrznych AM, Wroclaw, Poland

[9] Charite Teaching Hosp, Schlosspk Klin, Dept Internal Med, Berlin, Germany

来源：

LANCET | 2008年 / 371卷 / 9608期

关键词：

D O I：

10.1016/S0140-6736(08)60132-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Circadian rhythms are changed in patients with rheumatoid arthritis. A new modified-release delivery system has been developed which adapts the release of the administered glucocorticoid to the circadian rhythms of endogenous cortisol and disease symptoms to improve the benefit-risk ratio of glucocorticoid therapy in rheumatoid arthritis. We aimed to assess the efficacy and safety of a new modified-release prednisone tablet compared with immediate-release prednisone in patients with this disease. Methods In a 12-week, multicentre, randomised, double-blind trial, 288 patients with active rheumatoid arthritis were randomly assigned to either a modified-release prednisone tablet (n=144) or to an immediate-release prednisone tablet (n=144). The modified-release tablet was taken at bedtime and prednisone was released with a delay of 4 h after ingestion. This treatment was compared with morning administration of immediate-release prednisone as an active comparator. The primary outcome measure was duration of morning stiffness of the joints. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00146640. Findings The mean relative change in duration of morning stiffness of the joints from baseline to end of treatment was significantly higher with modified-release prednisone than with immediate-release prednisone (-22.7% vs-0.4%; difference=22. 4% [95% CI 0.49-44.30]; p=0.045). Patients in the prednisone modified-release group achieved a mean reduction of 44.0 (SD 136.6) min compared with baseline. The absolute difference between the treatment groups was 29.2 min (95% CI -2 . 59 to 61. 9) in favour of modified-release prednisone (p=0.072). The safety profile did not differ between treatments. Interpretation Modified-release prednisone is well tolerated, convenient to administer, and produces a clinically relevant reduction of morning stiffness of the joints in addition to all known therapeutic effects of immediate-release prednisone.

引用

页码：205 / 214

页数：10

共 34 条

[1] Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials [J].

Aletaha, D ;

Ward, MM .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (02) :227-233

[2] Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components [J].

Aletaha, Daniel ;

Smolen, Josef ;

Ward, Michael M. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2784-2792

[3]

Almawi WY, 2001, MOD ASP IMMUNOBIOL, V2, P78

[4]

[Anonymous], SF 36 PHYS MENT HLTH

[5] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[6] CIRCADIAN-RHYTHM OF SERUM INTERLEUKIN-6 IN RHEUMATOID-ARTHRITIS [J].

ARVIDSON, NG ;

GUDBJORNSSON, B ;

ELFMAN, L ;

RYDEN, AC ;

TOTTERMAN, TH ;

HALLGREN, R .

ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (08) :521-524

[7] The timing of glucocorticoid administration in rheumatoid arthritis [J].

Arvidson, NG ;

Gudbjornsson, B ;

Larsson, A ;

Hallgren, R .

ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (01) :27-31

[8] Developments in glucocorticoid therapy [J].

Bijlsma, JWJ ;

Saag, KG ;

Buttgereit, F ;

da Silva, JAP .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2005, 31 (01) :1-+

[9]

Buttgereit F, 2005, LANCET, V365, P801

[10] Glucocorticoids in the treatment of rheumatic diseases - An update on the mechanisms of action [J].

Buttgereit, F ;

Straub, RH ;

Wehling, M ;

Burmester, GR .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3408-3417

← 1 2 3 4 →